Synopsis
Synopsis
0
KDMF
0
VMF
0
FDF
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
Annual Reports
NA
1. L 705,126
2. L 705126
3. L-705,126
4. L-705126
5. Maxalt
6. Mk 0462
7. Mk 462
8. Mk-0462
9. Mk-462
10. N,n-dimethyl-2-(5-(1,2,4-triazol-1-ylmethyl)-1h-indole-3-yl)ethylamine
11. Rizatriptan
1. 145202-66-0
2. Maxalt
3. Rizatriptan (benzoate)
4. Maxalt-mlt
5. Mk 462
6. Mk-462
7. Mk-0462
8. 2-(5-((1h-1,2,4-triazol-1-yl)methyl)-1h-indol-3-yl)-n,n-dimethylethanamine Benzoate
9. Nsc-758919
10. Wr978s7qhh
11. Rizatriptan Benzoate (maxalt)
12. N,n-dimethyl-2-[5-(1,2,4-triazol-1-ylmethyl)-1h-indol-3-yl]ethylamine Benzoate
13. 3-(2-(dimethylamino)ethyl)-5-(1h-1,2,4-triazol-1-ylmethyl)indole Monobenzoate
14. 1h-indole-3-ethanamine, N,n-dimethyl-5-(1h-1,2,4-triazol-1-ylmethyl)-, Monobenzoate
15. 2-(5-((1h-1,2,4-triazol-1-yl)methyl)-1h-indol-3-yl)-n,n-dimethylethan-1-amine Benzoate
16. Benzoic Acid;n,n-dimethyl-2-[5-(1,2,4-triazol-1-ylmethyl)-1h-indol-3-yl]ethanamine
17. Rizatriptanbenzoate
18. N,n-dimethyl-5-(1h-1,2,4-triazol-1-ylmethyl)-1h-indole-3-ethanamine Benzoate
19. Rizatriptan Benzoate [usan]
20. Mk 0462
21. Unii-wr978s7qhh
22. L 705126
23. L 705,126
24. L-705,126
25. Rizatriptan Benzoate [usan:usp]
26. Rizatrimptan Benzoate
27. Rizatriptane Benzoate
28. Rizatriptan, Benzoate
29. Mk-462 Benzoate
30. Schembl41226
31. Mls001424197
32. Chebi:8875
33. Rizatriptan Benzoate Salt
34. Chembl1201032
35. Rizatriptan Benzoate (jan/usp)
36. Amy8935
37. Dtxsid20162937
38. Rhb-103
39. Rizatriptan Benzoate [mi]
40. Hms2051b16
41. Hms2093k08
42. Hms2235m18
43. Hms3369i15
44. Hms3393b16
45. Hms3655k09
46. Hms3715d08
47. Hms3884k21
48. Pharmakon1600-01505189
49. Rizatriptan Benzoate [jan]
50. Act04340
51. Bcp02149
52. Hy-b0206
53. Int-0008
54. Rizatriptan Benzoate [vandf]
55. Ac-734
56. Mfcd00866224
57. Nsc758919
58. Rizatriptan Benzoate [mart.]
59. Rizatriptan Benzoate [usp-rs]
60. Rizatriptan Benzoate [who-dd]
61. Akos015855933
62. Ab07521
63. Ccg-101039
64. Ks-1189
65. Nc00289
66. Nsc 758919
67. Rizatriptan Benzoate [orange Book]
68. Smr000525252
69. Rizatriptan Benzoate [ep Monograph]
70. Db-015783
71. Rizatriptan Benzoate [usp Monograph]
72. Rizatriptan Benzoate Salt, >=98% (hplc)
73. Ft-0631171
74. R0107
75. R0181
76. S1607
77. Sw197669-2
78. D00675
79. 202r660
80. A808337
81. Sr-01000763588
82. J-008071
83. J-524222
84. Sr-01000763588-3
85. Q27292788
86. Rizatriptan Benzoate, European Pharmacopoeia (ep) Reference Standard
87. Rizatriptan Benzoate, United States Pharmacopeia (usp) Reference Standard
88. Dimethyl-[2-(5-[1,2,4]triazol-1-ylmethyl-1h-indol-3-yl)-ethyl]-amine Benzoate
89. N,n-dimethyl-2-[5-(1,2,4-triazol-1-ylmethyl)-1h-indol-3-yl]ethanamine Benzoate
90. Rizatriptan For System Suitability, European Pharmacopoeia (ep) Reference Standard
Molecular Weight | 391.5 g/mol |
---|---|
Molecular Formula | C22H25N5O2 |
Hydrogen Bond Donor Count | 2 |
Hydrogen Bond Acceptor Count | 5 |
Rotatable Bond Count | 6 |
Exact Mass | 391.20082506 g/mol |
Monoisotopic Mass | 391.20082506 g/mol |
Topological Polar Surface Area | 87 Ų |
Heavy Atom Count | 29 |
Formal Charge | 0 |
Complexity | 412 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
1 of 4 | |
---|---|
Drug Name | Maxalt |
PubMed Health | Rizatriptan (By mouth) |
Drug Classes | Antimigraine |
Drug Label | MAXALTCOPYRIGHT 1998, 2006 Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.All rights reserved contains rizatriptan benzoate, a selective 5-hydroxytryptamine1B/1D (5-HT1B/1D) receptor agonist.Rizatriptan benzoate is described chemical |
Active Ingredient | Rizatriptan benzoate |
Dosage Form | Tablet |
Route | Oral |
Strength | eq 5mg base; eq 10mg base |
Market Status | Prescription |
Company | Merck |
2 of 4 | |
---|---|
Drug Name | Rizatriptan benzoate |
Drug Label | MAXALTCOPYRIGHT 1998, 2006 Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.All rights reserved contains rizatriptan benzoate, a selective 5-hydroxytryptamine1B/1D (5-HT1B/1D) receptor agonist.Rizatriptan benzoate is described chemical |
Active Ingredient | Rizatriptan benzoate |
Dosage Form | Tablet; Tablet, orally disintegrating |
Route | Oral |
Strength | eq 5mg base; eq 10mg base |
Market Status | Prescription |
Company | Mylan Pharms; Apotex; Aurobindo Pharma; Natco Pharma; Sandoz; Invagen Pharms; Cipla; Sun Pharma Global; Glenmark Generics; Emcure Pharms; Teva Pharms; Macleods Pharms |
3 of 4 | |
---|---|
Drug Name | Maxalt |
PubMed Health | Rizatriptan (By mouth) |
Drug Classes | Antimigraine |
Drug Label | MAXALTCOPYRIGHT 1998, 2006 Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.All rights reserved contains rizatriptan benzoate, a selective 5-hydroxytryptamine1B/1D (5-HT1B/1D) receptor agonist.Rizatriptan benzoate is described chemical |
Active Ingredient | Rizatriptan benzoate |
Dosage Form | Tablet |
Route | Oral |
Strength | eq 5mg base; eq 10mg base |
Market Status | Prescription |
Company | Merck |
4 of 4 | |
---|---|
Drug Name | Rizatriptan benzoate |
Drug Label | MAXALTCOPYRIGHT 1998, 2006 Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.All rights reserved contains rizatriptan benzoate, a selective 5-hydroxytryptamine1B/1D (5-HT1B/1D) receptor agonist.Rizatriptan benzoate is described chemical |
Active Ingredient | Rizatriptan benzoate |
Dosage Form | Tablet; Tablet, orally disintegrating |
Route | Oral |
Strength | eq 5mg base; eq 10mg base |
Market Status | Prescription |
Company | Mylan Pharms; Apotex; Aurobindo Pharma; Natco Pharma; Sandoz; Invagen Pharms; Cipla; Sun Pharma Global; Glenmark Generics; Emcure Pharms; Teva Pharms; Macleods Pharms |
Serotonin Receptor Agonists
Endogenous compounds and drugs that bind to and activate SEROTONIN RECEPTORS. Many serotonin receptor agonists are used as ANTIDEPRESSANTS; ANXIOLYTICS; and in the treatment of MIGRAINE DISORDERS. (See all compounds classified as Serotonin Receptor Agonists.)
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 25623
Submission : 2011-12-22
Status : Active
Type : II
NDC Package Code : 64567-0013
Start Marketing Date : 2009-10-28
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
Available Reg Filing : ASMF |
GDUFA
DMF Review : Reviewed
Rev. Date : 2021-06-02
Pay. Date : 2021-05-27
DMF Number : 20781
Submission : 2007-08-21
Status : Active
Type : II
Certificate Number : R1-CEP 2012-268 - Rev 00
Issue Date : 2020-05-15
Type : Chemical
Substance Number : 2585
Status : Valid
Date of Issue : 2019-06-26
Valid Till : 2022-06-25
Written Confirmation Number : WC-0014
Address of the Firm :
NDC Package Code : 63850-7119
Start Marketing Date : 2016-01-18
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
GDUFA
DMF Review : Reviewed
Rev. Date : 2014-07-01
Pay. Date : 2014-03-24
DMF Number : 24177
Submission : 2010-09-27
Status : Active
Type : II
Date of Issue : 2024-04-23
Valid Till : 2027-04-22
Written Confirmation Number : WC-0170
Address of the Firm :
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 22676
Submission : 2009-03-31
Status : Active
Type : II
Certificate Number : R1-CEP 2012-108 - Rev 02
Issue Date : 2022-12-05
Type : Chemical
Substance Number : 2585
Status : Valid
Registration Number : 228MF10064
Registrant's Address : 4th Floor, OIA House, 470, Cardinal Gracious Road, Andheri East Mumbai 400099, Maharashtra, India
Initial Date of Registration : 2016-02-24
Latest Date of Registration : --
Date of Issue : 2022-06-07
Valid Till : 2025-06-25
Written Confirmation Number : WC-0057n
Address of the Firm :
NDC Package Code : 66039-835
Start Marketing Date : 2009-03-31
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 23581
Submission : 2010-05-28
Status : Active
Type : II
Date of Issue : 2022-08-08
Valid Till : 2025-07-14
Written Confirmation Number : WC-0168
Address of the Firm :
GDUFA
DMF Review : Reviewed
Rev. Date : 2014-05-28
Pay. Date : 2014-03-06
DMF Number : 27991
Submission : 2014-03-11
Status : Active
Type : II
Certificate Number : CEP 2014-290 - Rev 01
Issue Date : 2024-11-07
Type : Chemical
Substance Number : 2585
Status : Valid
Date of Issue : 2022-06-30
Valid Till : 2025-07-28
Written Confirmation Number : WC-0063
Address of the Firm :
NDC Package Code : 53747-043
Start Marketing Date : 2014-03-11
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 28634
Submission : 2014-09-08
Status : Active
Type : II
Registration Number : 227MF10229
Registrant's Address : No. 168 Kai-Yuan Rd. , Hsin-Ying Tainan City, 73055. Taiwan
Initial Date of Registration : 2015-09-03
Latest Date of Registration : --
GDUFA
DMF Review : Reviewed
Rev. Date : 2013-10-18
Pay. Date : 2013-05-24
DMF Number : 23066
Submission : 2009-08-26
Status : Active
Type : II
Certificate Number : R1-CEP 2013-028 - Rev 00
Issue Date : 2020-05-18
Type : Chemical
Substance Number : 2585
Status : Valid
Registration Number : 228MF10019
Registrant's Address : Plot No. 72, H. No.8-2-334/3&4 Road No. 5, Opp. SBI Executive Enclave, Banjara Hills, Hyderabad, Telangana, India
Initial Date of Registration : 2016-01-14
Latest Date of Registration : --
Date of Issue : 2019-06-26
Valid Till : 2022-07-02
Written Confirmation Number : WC-0071
Address of the Firm :
NDC Package Code : 67835-5016
Start Marketing Date : 2009-05-13
End Marketing Date : 2025-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
DRUG PRODUCT COMPOSITIONS
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
REF. STANDARDS & IMPURITIES
ANALYTICAL
ABOUT THIS PAGE
A Rizatriptan Benzoate manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Rizatriptan Benzoate, including repackagers and relabelers. The FDA regulates Rizatriptan Benzoate manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Rizatriptan Benzoate API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Rizatriptan Benzoate manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Rizatriptan Benzoate supplier is an individual or a company that provides Rizatriptan Benzoate active pharmaceutical ingredient (API) or Rizatriptan Benzoate finished formulations upon request. The Rizatriptan Benzoate suppliers may include Rizatriptan Benzoate API manufacturers, exporters, distributors and traders.
click here to find a list of Rizatriptan Benzoate suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Rizatriptan Benzoate DMF (Drug Master File) is a document detailing the whole manufacturing process of Rizatriptan Benzoate active pharmaceutical ingredient (API) in detail. Different forms of Rizatriptan Benzoate DMFs exist exist since differing nations have different regulations, such as Rizatriptan Benzoate USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Rizatriptan Benzoate DMF submitted to regulatory agencies in the US is known as a USDMF. Rizatriptan Benzoate USDMF includes data on Rizatriptan Benzoate's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Rizatriptan Benzoate USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Rizatriptan Benzoate suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Rizatriptan Benzoate Drug Master File in Japan (Rizatriptan Benzoate JDMF) empowers Rizatriptan Benzoate API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Rizatriptan Benzoate JDMF during the approval evaluation for pharmaceutical products. At the time of Rizatriptan Benzoate JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Rizatriptan Benzoate suppliers with JDMF on PharmaCompass.
A Rizatriptan Benzoate CEP of the European Pharmacopoeia monograph is often referred to as a Rizatriptan Benzoate Certificate of Suitability (COS). The purpose of a Rizatriptan Benzoate CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Rizatriptan Benzoate EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Rizatriptan Benzoate to their clients by showing that a Rizatriptan Benzoate CEP has been issued for it. The manufacturer submits a Rizatriptan Benzoate CEP (COS) as part of the market authorization procedure, and it takes on the role of a Rizatriptan Benzoate CEP holder for the record. Additionally, the data presented in the Rizatriptan Benzoate CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Rizatriptan Benzoate DMF.
A Rizatriptan Benzoate CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Rizatriptan Benzoate CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Rizatriptan Benzoate suppliers with CEP (COS) on PharmaCompass.
A Rizatriptan Benzoate written confirmation (Rizatriptan Benzoate WC) is an official document issued by a regulatory agency to a Rizatriptan Benzoate manufacturer, verifying that the manufacturing facility of a Rizatriptan Benzoate active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Rizatriptan Benzoate APIs or Rizatriptan Benzoate finished pharmaceutical products to another nation, regulatory agencies frequently require a Rizatriptan Benzoate WC (written confirmation) as part of the regulatory process.
click here to find a list of Rizatriptan Benzoate suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Rizatriptan Benzoate as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Rizatriptan Benzoate API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Rizatriptan Benzoate as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Rizatriptan Benzoate and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Rizatriptan Benzoate NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Rizatriptan Benzoate suppliers with NDC on PharmaCompass.
Rizatriptan Benzoate Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Rizatriptan Benzoate GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Rizatriptan Benzoate GMP manufacturer or Rizatriptan Benzoate GMP API supplier for your needs.
A Rizatriptan Benzoate CoA (Certificate of Analysis) is a formal document that attests to Rizatriptan Benzoate's compliance with Rizatriptan Benzoate specifications and serves as a tool for batch-level quality control.
Rizatriptan Benzoate CoA mostly includes findings from lab analyses of a specific batch. For each Rizatriptan Benzoate CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Rizatriptan Benzoate may be tested according to a variety of international standards, such as European Pharmacopoeia (Rizatriptan Benzoate EP), Rizatriptan Benzoate JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Rizatriptan Benzoate USP).
LOOKING FOR A SUPPLIER?